An official website of the United States government
Home
Name
Avelumab
Alternate Names
Bavencio
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Monoclonal antibody
NSC Number
None
Primary Site
Skin
Bladder
Histology
Remarks
6/30/2020 The FDA approved avelumab (BAVENCIO) for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.
May 14, 2019: FDA approved avelumab (BAVENCIO) in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC).
5/9/2017: The U.S. Food and Drug Administration granted accelerated approval to avelumab for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
3/24/2017:The U.S. Food and Drug Administration granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer.
May 14, 2019: FDA approved avelumab (BAVENCIO) in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC).
5/9/2017: The U.S. Food and Drug Administration granted accelerated approval to avelumab for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
3/24/2017:The U.S. Food and Drug Administration granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer.
Coding
This drug should be coded
